Differential effects of testosterone on circulating neutrophils, monocytes, and platelets in men: Findings from two trials

Abstract

Background Testosterone treatment increases erythrocytes in men, but its effects on leukocyte and platelet counts are unknown and could affect its safety. Objective To determine whether testosterone affects circulating leukocytes and platelets in men. Methods Secondary analyses of two randomized testosterone trials were performed: the 5α‐reductase (5aR) and OPTIMEN trials. In 5aR trial, 102 healthy men, 21‐50 years (mean age 38), received a long‐acting GnRH agonist, and 50, 125, 300, or 600 mg/week testosterone enanthate (TE) plus placebo or 2.5 mg/day dutasteride for 20 weeks. In OPTIMEN, 78 functionally limited men, ≥65 years (mean age 72) with protein intake ≤ 0.83 g kg−1 day−1, were randomized to controlled diets with 0.8 g kg−1 day−1 protein or 1.3 g kg−1 day−1 protein plus placebo or TE (100 mg/week) for 6 months. Changes from baseline in total and differential leukocyte count, and platelet count were evaluated. Results In 5aR, testosterone administration was associated with increases in total leukocyte (estimated change from baseline 40, 490, 1230, and 1280 cells/µL, P < .001), neutrophil (65.1, 436.1, 1177.2, and 1192.2 cells/µL, P < .001), monocyte (−20.2, 24.5, 90.6, and 143.9 cells/µL, P < .001), platelet (−7.3, 8.4, 8.7, and 8.9 × 103 cells/µL, P = .033), and erythrocyte counts. Testosterone did not affect absolute lymphocyte count. Similar increase in total leukocyte count was observed with testosterone treatment in OPTIMEN (change 0.77 × 103 cells/µL, P vs placebo = 0.004). Conclusions Testosterone administration in men differentially increases neutrophil and monocyte counts. These findings, together with its erythropoietic effects, suggest that testosterone promotes the differentiation of hematopoietic progenitors into the myeloid lineage. These findings have potential mechanistic, therapeutic, and safety implications.

Exploring Pleiotropic Effects of Lipid Modifiers and Targets on Measures of the Coagulation System with Genetics

“…18,20 Notably, genetically mimicked effects of statins reduced platelet count more in men than women (Supplementary Table 2) which is consistent with previous findings on sex-specific mechanisms. 21,41 Identification of which coagulation factors are affected most by statins in men and women and their relevance to cardiovascular disease might help target the use of statins, anticoagulants, antiplatelet agents and their combination. These findings might also be informative about the development of interventions targeting lipid metabolism, via LPL, as they suggest an off-target potentially harmful effects via decreasing aPTT, and possibly raising platelet count.…”

Short-Term Haematogical Effects of Androgen Deprivation and Radiotherapy in Prostate Cancer Patients

“…showed no effect on total leukocyte counts, while another [3] showed a 9% decrease. There were no specifics as to granulocyte or lymphocyte counts in these DOI: 10.4236/oju.2021.114011 108 Open Journal of Urology studies, although in clinical studies [8] with the administration of testosterone, there was an increase in neutrophils. Chuang [5] reported a decrease in neutrophils in castrated mice, but non-significant decrease in neutrophils in 33 men after castration.…”

Diclofenac predisposes benign prostate hyperplasia in fat feed albino rats

“…12 Testosterone promotes the differentiation of hematopoietic progenitors into the myeloid lineage as indicated in human trials. 13 The decrease in some blood parameters caused by this drug may be attributed to its harmful effects on bone marrow and haematopoietic organs. 14 The HB, PCV and MCV levels all showed varying alterations in Table 5.…”